US Patent

US9750726 — Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist

Formulation · Assigned to Glaxo Group Ltd · Expires 2030-11-29 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent provides combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist for inhaled administration via the nose or mouth.

USPTO Abstract

Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.

Drugs covered by this patent

Patent Metadata

Patent number
US9750726
Jurisdiction
US
Classification
Formulation
Expires
2030-11-29
Drug substance claim
No
Drug product claim
Yes
Assignee
Glaxo Group Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.